TY - JOUR
T1 - Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma
AU - Carril-Ajuria, Lucia
AU - Lavaud, Pernelle
AU - Dalban, Cecile
AU - Negrier, Sylvie
AU - Gravis, Gwénaëlle
AU - Motzer, Robert J.
AU - Chevreau, Christine
AU - Tannir, Nizar M.
AU - Oudard, Stéphane
AU - McDermott, David F.
AU - Laguerre, Brigitte
AU - Hammers, Hans J.
AU - Barthelemy, Philippe
AU - Plimack, Elizabeth R.
AU - Borchiellini, Delphine
AU - Gross-Goupil, Marine
AU - Jiang, Ruiyun
AU - Lee, Chung Wei
AU - de Silva, Heshani
AU - Rini, Brian I.
AU - Escudier, Bernard
AU - Albigès, Laurence
N1 - Publisher Copyright:
© 2024
PY - 2024/6
Y1 - 2024/6
N2 - BACKGROUND: The Lung Immune Prognostic Index (LIPI) is associated with immune checkpoint inhibitors (ICI) outcomes across different solid tumors, particularly in non-small cell lung cancer. Data regarding the prognostic and/or predictive role of LIPI in metastatic renal cell carcinoma (mRCC) are still scarce. The aim of this study was to evaluate whether LIPI could be predictive of survival in mRCC patients.METHODS: We used patient level data from three different prospective studies (NIVOREN trial: nivolumab; TORAVA trial: VEGF/VEGFR-targeted therapy (TT); CheckMate 214: nivolumab-ipilimumab vs sunitinib). LIPI was calculated based on a derived neutrophils/(leukocyte-neutrophil) ratio > 3 and lactate-dehydrogenase >upper limit of normal, classifying patients into three groups (LIPI good, 0 factors;LIPI intermediate (int), 1 factor;LIPI poor, 2 factors) and/or into two groups (LIPI good, 0 factors;LIPI int/poor, 1-2 factors) according to trial sample size. Primary and secondary endpoints were overall survival (OS) and progression-free survival (PFS).RESULTS: In the Nivolumab dataset (n = 619), LIPI was significantly associated with OS (LIPI-good 30.1 vs 13.8 months in the LIPI int/poor; HR= 0.47) and PFS (HR=0.74). In the VEGF/VEGFR-TT dataset (n = 159), only a correlation with PFS was observed. In the CheckMate214 dataset (n = 1084), LIPI was significantly associated with OS (nivolumab-ipilimumab OS LIPI good vs int/poor: HR=0.55, p < 0.0001; sunitinib: OS LIPI good vs int/poor: 0.38, p < 0.0001) in both treatment groups in univariate and multivariate analysis.CONCLUSIONS: Pretreatment-LIPI correlated with worse survival outcomes in mRCC treated with either ICI or antiangiogenic therapy, confirming LIPI's prognostic role in mRCC irrespective of systemic treatment used.
AB - BACKGROUND: The Lung Immune Prognostic Index (LIPI) is associated with immune checkpoint inhibitors (ICI) outcomes across different solid tumors, particularly in non-small cell lung cancer. Data regarding the prognostic and/or predictive role of LIPI in metastatic renal cell carcinoma (mRCC) are still scarce. The aim of this study was to evaluate whether LIPI could be predictive of survival in mRCC patients.METHODS: We used patient level data from three different prospective studies (NIVOREN trial: nivolumab; TORAVA trial: VEGF/VEGFR-targeted therapy (TT); CheckMate 214: nivolumab-ipilimumab vs sunitinib). LIPI was calculated based on a derived neutrophils/(leukocyte-neutrophil) ratio > 3 and lactate-dehydrogenase >upper limit of normal, classifying patients into three groups (LIPI good, 0 factors;LIPI intermediate (int), 1 factor;LIPI poor, 2 factors) and/or into two groups (LIPI good, 0 factors;LIPI int/poor, 1-2 factors) according to trial sample size. Primary and secondary endpoints were overall survival (OS) and progression-free survival (PFS).RESULTS: In the Nivolumab dataset (n = 619), LIPI was significantly associated with OS (LIPI-good 30.1 vs 13.8 months in the LIPI int/poor; HR= 0.47) and PFS (HR=0.74). In the VEGF/VEGFR-TT dataset (n = 159), only a correlation with PFS was observed. In the CheckMate214 dataset (n = 1084), LIPI was significantly associated with OS (nivolumab-ipilimumab OS LIPI good vs int/poor: HR=0.55, p < 0.0001; sunitinib: OS LIPI good vs int/poor: 0.38, p < 0.0001) in both treatment groups in univariate and multivariate analysis.CONCLUSIONS: Pretreatment-LIPI correlated with worse survival outcomes in mRCC treated with either ICI or antiangiogenic therapy, confirming LIPI's prognostic role in mRCC irrespective of systemic treatment used.
KW - Antiangiogenics
KW - Biomarkers
KW - LIPI
KW - Prognosis
KW - Renal cell carcinoma
KW - immune checkpoint inhibitors
KW - Kidney Neoplasms/drug therapy
KW - Prospective Studies
KW - Immune Checkpoint Inhibitors/therapeutic use
KW - Humans
KW - Middle Aged
KW - Sunitinib/therapeutic use
KW - Male
KW - Nivolumab/therapeutic use
KW - Biomarkers, Tumor/analysis
KW - Lung Neoplasms/drug therapy
KW - Progression-Free Survival
KW - Adult
KW - Carcinoma, Renal Cell/drug therapy
KW - Female
KW - Aged
UR - http://www.scopus.com/inward/record.url?scp=85190744548&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2024.114048
DO - 10.1016/j.ejca.2024.114048
M3 - Article
C2 - 38653033
AN - SCOPUS:85190744548
SN - 0959-8049
VL - 204
SP - 114048
JO - European Journal of Cancer
JF - European Journal of Cancer
M1 - 114048
ER -
